Mateos Manteca, M. V., Nahi, H., Legieć, W., Grosicki, S., Vorobyev, V., Spicka, I., . . . Usmani, S. Z. (2020). Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): A multicentre, open-label, non-inferiority, randomised, phase 3 trial.
Citación estilo ChicagoMateos Manteca, María Victoria, et al. Subcutaneous Versus Intravenous Daratumumab in Patients With Relapsed or Refractory Multiple Myeloma (COLUMBA): A Multicentre, Open-label, Non-inferiority, Randomised, Phase 3 Trial. 2020.
Cita MLAMateos Manteca, María Victoria, et al. Subcutaneous Versus Intravenous Daratumumab in Patients With Relapsed or Refractory Multiple Myeloma (COLUMBA): A Multicentre, Open-label, Non-inferiority, Randomised, Phase 3 Trial. 2020.